DISEASE CHARACTERISTICS:

• Minority (non-white) female cancer survivor

  • No active cancer based on physical exam and radiographic images obtained within the past 3 months
• Concerned with sexual quality of life
• Must express interest in sexual activity

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Hemoglobin ≥ 10 g/dL
• Creatinine ≤ 1.5 mg/dL
• WBC ≥ 2,000/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin ≤ 1.5 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• No mental, medical, or physical disorder known to affect sexual function
• No history of allergic reactions attributed to compounds of similar chemical or biological composition to ArginMax®

• No uncontrolled intercurrent illness including, but not limited to, the following:

  • Ongoing or active infection
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Cardiac arrhythmia
  • Psychiatric illness or social situation that would preclude study compliance and/or ability for sexual function

PRIOR CONCURRENT THERAPY:

• At least 1 month since prior participation in another study with an investigational drug or device
• At least 6 months since prior cancer therapy

• No concurrent blood thinner, including any of the following:

  • acetylsalicylic acid (aspirin) (one 81 mg aspirin, or one baby aspirin per day allowed)
  • warfarin (low-dose warfarin for catheter patency allowed)
  • dipyridamole
  • heparin
  • enoxaparin
• No concurrent surgery
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No concurrent EGb761 (ginkgo biloba)
• Concurrent hormonal therapy and trastuzumab (Herceptin®) allowed